DiaMedica Therapeutics Inc. (DMAC) Stock Forecast
DMAC analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $15.50 average of analyst targets
- Upside to target
- +104.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.20
- 52-week range
- $5.33 – $9.39
DMAC analyst ratings
5 analystsNumber of analysts at each rating.
DMAC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DMAC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.23 | −$0.19 | −$0.17 | −22.1% | 4 |
| Current fiscal year (2026) | −$0.81 | −$0.88 | −$0.76 | −$0.70 | −16.1% | 4 |
| Next fiscal year (2027) | −$0.81 | −$1.05 | −$0.59 | −$0.81 | +0.5% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DMAC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
DMAC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DMAC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −2.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.83 | −$0.83 | −$0.81 | −$0.81 | −$0.81 | −2.1% | 3 up · 0 down |
| Next fiscal year (2027) | −$0.88 | −$0.88 | −$0.81 | −$0.81 | −$0.81 | −8.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DMAC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DMAC beat in 9 of 12.
What analysts expect from DMAC
5 analysts cover DiaMedica Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.50, 104.8% above the latest close of $7.57. Analysts expect earnings of −$0.81 per share for 2026, −16.1% from a year earlier. For 2027 the average estimate is −$0.81 per share. DiaMedica Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: DMAC income statement, DMAC key metrics, DMAC chart. See the DMAC stock overview for the latest quote and news.
DMAC forecast FAQ
What is DiaMedica Therapeutics's price target?
The average analyst price target for DiaMedica Therapeutics is $15.50, 104.8% above the latest close of $7.57.
Is DiaMedica Therapeutics a buy, hold or sell?
Of 5 analysts covering DiaMedica Therapeutics, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is DiaMedica Therapeutics's EPS forecast?
Analysts forecast −$0.81 per share for 2026 (range −$0.88 to −$0.76); for 2027 the estimate is −$0.81.
When does DiaMedica Therapeutics report earnings?
DiaMedica Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.20.
Does DiaMedica Therapeutics usually beat earnings estimates?
DiaMedica Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.